- Home
- ZDGE vs OKUR Comparison
ZDGE vs OKUR Comparison
Compare ZDGE & OKUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZDGE
- OKUR
- Stock Information
- Founded
- ZDGE 2008
- OKUR 2011
- Country
- ZDGE United States
- OKUR United States
- Employees
- ZDGE N/A
- OKUR N/A
- Industry
- ZDGE Computer Software: Prepackaged Software
- OKUR
- Sector
- ZDGE Technology
- OKUR
- Exchange
- ZDGE Nasdaq
- OKUR NYSE
- Market Cap
- ZDGE 40.3M
- OKUR 34.9M
- IPO Year
- ZDGE N/A
- OKUR N/A
- Fundamental
- Price
- ZDGE $3.99
- OKUR $2.52
- Analyst Decision
- ZDGE
- OKUR Strong Buy
- Analyst Count
- ZDGE 0
- OKUR 4
- Target Price
- ZDGE N/A
- OKUR $32.25
- AVG Volume (30 Days)
- ZDGE 418.5K
- OKUR 94.3K
- Earning Date
- ZDGE 06-12-2025
- OKUR 08-14-2025
- Dividend Yield
- ZDGE N/A
- OKUR N/A
- EPS Growth
- ZDGE N/A
- OKUR N/A
- EPS
- ZDGE N/A
- OKUR N/A
- Revenue
- ZDGE $29,511,000.00
- OKUR N/A
- Revenue This Year
- ZDGE N/A
- OKUR N/A
- Revenue Next Year
- ZDGE $1.07
- OKUR N/A
- P/E Ratio
- ZDGE N/A
- OKUR N/A
- Revenue Growth
- ZDGE 1.27
- OKUR N/A
- 52 Week Low
- ZDGE $1.73
- OKUR $1.70
- 52 Week High
- ZDGE $4.38
- OKUR $20.00
- Technical
- Relative Strength Index (RSI)
- ZDGE 84.28
- OKUR N/A
- Support Level
- ZDGE $2.55
- OKUR N/A
- Resistance Level
- ZDGE $4.37
- OKUR N/A
- Average True Range (ATR)
- ZDGE 0.36
- OKUR 0.00
- MACD
- ZDGE 0.11
- OKUR 0.00
- Stochastic Oscillator
- ZDGE 79.29
- OKUR 0.00
About ZDGE Zedge Inc. Class B
Zedge Inc provides content distribution platforms. Its content platform enables consumers to personalize their mobile devices with free, high-quality ringtones, wallpapers, home screen app icons, widgets and notification sounds as well as paint, a generative AI wallpaper maker, GuruShots, a skill-based photo challenge game, and Emojipedia. The company also launched a Zedge app. It has two reportable segments, which are the Zedge Marketplace and GuruShots.
About OKUR ONKURE THERAPEUTICS INC
OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing top-tier precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. The company operates in one operating segment which is clinical research. It has a pipeline of tumor-agnostic candidates that are designed to achieve optimal efficacy and tolerability.